125 related articles for article (PubMed ID: 38083866)
81. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
Neckers L
Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
[TBL] [Abstract][Full Text] [Related]
82. Hsp90 inhibitors and drugs from fragment and virtual screening.
Roughley S; Wright L; Brough P; Massey A; Hubbard RE
Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
[TBL] [Abstract][Full Text] [Related]
83. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH
Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977
[TBL] [Abstract][Full Text] [Related]
84. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
85. A silicon-containing aryl/penta-1,4-dien-3-one/amine hybrid exhibits antiproliferative effects on breast cancer cells by targeting the HSP90 C-terminus without inducing heat-shock response.
Liao YT; Du XY; Wang M; Zheng CX; Li D; Chen CH; Li RT; Shao LD
RSC Med Chem; 2023 Dec; 14(12):2625-2639. PubMed ID: 38107168
[TBL] [Abstract][Full Text] [Related]
86. Structure-Activity Relationships of Benzothiazole-Based Hsp90 C-Terminal-Domain Inhibitors.
Dernovšek J; Zajec Ž; Durcik M; Mašič LP; Gobec M; Zidar N; Tomašič T
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452244
[TBL] [Abstract][Full Text] [Related]
87. Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.
Malayeri SO; Abnous K; Arab A; Akaberi M; Mehri S; Zarghi A; Ghodsi R
Bioorg Med Chem; 2017 Feb; 25(3):1294-1302. PubMed ID: 28073608
[TBL] [Abstract][Full Text] [Related]
88. Hsp90 inhibitors identified from a library of novobiocin analogues.
Yu XM; Shen G; Neckers L; Blake H; Holzbeierlein J; Cronk B; Blagg BS
J Am Chem Soc; 2005 Sep; 127(37):12778-9. PubMed ID: 16159253
[TBL] [Abstract][Full Text] [Related]
89. A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response.
Kim JY; Cho TM; Park JM; Park S; Park M; Nam KD; Ko D; Seo J; Kim S; Jung E; Farrand L; Nguyen CT; Hoang VH; Thanh La M; Ann J; Nam G; Park HJ; Lee J; Kim YJ; Seo JH
Oncogene; 2022 Jun; 41(23):3289-3297. PubMed ID: 35501463
[TBL] [Abstract][Full Text] [Related]
90. A Coumarin-Imidazothiadiazole Derivative, SP11 Abrogates Tumor Growth by Targeting HSP90 and Its Client Proteins.
Nirgude S; Shahana M V ; Ravindran F; Kumar S; Sharma S; Mahadeva R; Mhatre A; Karki SS; Choudhary B
Molecules; 2023 Jul; 28(13):. PubMed ID: 37446888
[TBL] [Abstract][Full Text] [Related]
91. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
92. Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery.
Audisio D; Messaoudi S; Cegielkowski L; Peyrat JF; Brion JD; Methy-Gonnot D; Radanyi C; Renoir JM; Alami M
ChemMedChem; 2011 May; 6(5):804-15. PubMed ID: 21374821
[TBL] [Abstract][Full Text] [Related]
93. Recent advances toward the development of Hsp90 C-terminal inhibitors.
Amatya E; Blagg BSJ
Bioorg Med Chem Lett; 2023 Jan; 80():129111. PubMed ID: 36549397
[TBL] [Abstract][Full Text] [Related]
94. Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain.
Kumar Mv V; Ebna Noor R; Davis RE; Zhang Z; Sipavicius E; Keramisanou D; Blagg BSJ; Gelis I
Medchemcomm; 2018 Aug; 9(8):1323-1331. PubMed ID: 30151087
[TBL] [Abstract][Full Text] [Related]
95. Molecular docking and pharmacophore studies of heterocyclic compounds as Heat shock protein 90 (Hsp90) Inhibitors.
Baby ST; Sharma S; Enaganti S; Cherian PR
Bioinformation; 2016; 12(3):149-155. PubMed ID: 28232775
[TBL] [Abstract][Full Text] [Related]
96. Using NMR to identify binding regions for N and C-terminal Hsp90 inhibitors using Hsp90 domains.
McConnell JR; Dyson HJ; McAlpine SR
RSC Med Chem; 2021 Mar; 12(3):410-415. PubMed ID: 33898992
[TBL] [Abstract][Full Text] [Related]
97. Exploration and optimisation of structure-activity relationships of new triazole-based C-terminal Hsp90 inhibitors towards in vivo anticancer potency.
Dernovšek J; Zajec Ž; Poje G; Urbančič D; Sturtzel C; Goričan T; Grissenberger S; Ciura K; Woziński M; Gedgaudas M; Zubrienė A; Grdadolnik SG; Mlinarič-Raščan I; Rajić Z; Cotman AE; Zidar N; Distel M; Tomašič T
Biomed Pharmacother; 2024 Jun; 177():116941. PubMed ID: 38889640
[TBL] [Abstract][Full Text] [Related]
98. Synthesis of C3'-Foused Aryl/Penta-1,4-dien-3-one/Amine Hybrids as HSP90 C-Terminal Inhibitors.
Zheng CX; Liao YT; Wang HX; Yang C; Li D; Shao LD
Chem Biodivers; 2024 Jun; ():e202400870. PubMed ID: 38842484
[TBL] [Abstract][Full Text] [Related]
99. Development of Hsp90 C-terminal inhibitors with noviomimetics that manifest anti-proliferative activities.
Amatya E; Subramanian C; Cohen MS; Blagg BSJ
RSC Med Chem; 2024 Mar; 15(3):888-894. PubMed ID: 38516588
[TBL] [Abstract][Full Text] [Related]
100. Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio-
Liu Y; Li C; Li Y; Zhang S; Zhang N; Bian X; Tan S
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2290912. PubMed ID: 38083866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
